Researchers are excited about this new drug, a novel dual agonist showing remarkable data in early trials for size reduction . It acts by targeting several pathways : GLP-1 and GIP, which , when stimulated, support regulate cravings and enhance metabolism . Preliminary observations suggest substantial size management and possible advantages for pat